Cipla launches daptomycin for injection, 500 mg/vial
The single-dose vials are for intravenous use only
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Cipla
Cipla announces closure of USFDA inspection at Bengaluru facility
Following an inspection by USFDA at the company’s API manufacturing facility in Virgonagar, from July 15 to 19, the company has…
Stempeutics out licenses its stem cell product to Cipla for treating Diabetic Foot Ulcer
Under this agreement, Cipla will get the exclusive marketing rights for five years in India for DFU product with Stempeutics…
Is China the next land of opportunity?
As opportunities in developed markets saturate, India Pharma Inc is looking to optimise the growth potential in China. But what…
Cipla Foundation ties up with BJ Wadia Hospital
The paediatric palliative care unit will cater to children with all life-limiting and life-threatening conditions treated at the…
Indian’s big pharma companies finding new growth opportunities in China: Report
The Chinese pharma market is set to be worth $209 billion by 2022
Indian pharmaceutical companies are finding lucrative…
Cipla seeks favourable policy for domestic pharma cos, ease of doing biz
Cipla Executive Vice-Chairperson Samina Vaziralli said with the government returning for a second consecutive five-year term armed…
Notices issued to companies for introducing drugs without prior nod from NPPA: Government
The drugs include those used for treating conditions like diabetes, inflammation and chronic hepatitis C, among others
InvaGen receives final approval for Pregabalin Capsules
InvaGen’s Pregabalin Capsule is AB-rated generic therapeutic equivalent version of Pfizer’s Lyrica
Cipla EU and Jiangsu Acebright enter into joint venture
According to the agreement, the joint venture company will now become a subsidiary of Cipla